BRIEF—Johnson & Johnson presents data on HIV drug Symtuza

Johnson & Johnson has unveiled 96-week results from the pivotal Phase III AMBER study of Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide).

Symtuza is a once-daily darunavir-based single-tablet regimen (STR), for the treatment of human immunodeficiency virus type 1 (HIV-1).

Results show 85% of antiretroviral treatment (ART)-naïve adults with HIV-1 maintained virologic suppression at 96 weeks under treatment with Symtuza.

Chloe Orkin of Barts Health NHS Trust said: “The 96-week results from the AMBER study demonstrate that the darunavir-based single-tablet regimen has a good safety profile and efficacy and a high genetic barrier beyond the first year of treatment.”

“The regimen adds to the choices for patients who start and receive life-long HIV therapy.”